Potential Diagnostic Biomarkers for Aortic Dissection in the Emergency Department: the Aggrecan, Desmosine, D-dimer-Emergency Department (ADD-ED) Study

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The goal of this observational study is to determine the utility of desmosine, D-dimer and aggrecan as early diagnostic biomarkers in aortic dissection. The main questions it aims to answer are: * To investigate the plasma levels of selected biomarkers in ED patients with confirmed aortic dissection * To study the diagnostic performance of plasma levels of selected biomarkers for aortic dissection * To study the association between plasma levels of selected biomarkers and clinical outcomes

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• Age ≥ 18 years

• Presentation to the ED with first 24 hours of symptoms suggesting AD, including chest pain, upper back pain, syncope of unknown cause, symptoms of any acute perfusion deficit

• Confirmed AD

‣ the diagnosis of AD adjudicated by an independent expert panel at hospital discharge or death, whichever comes first

⁃ The expert panel will consist of (1) a specialist in Emergency Medicine and (2) a specialist in Cardiology and (3) a specialist in Cardiothoracic Surgery.

Locations
Other Locations
Hong Kong Special Administrative Region
Prince of Wales Hospital
RECRUITING
Shatin
Contact Information
Primary
Colin A Graham
cagraham@cuhk.edu.hk
+85235051033
Backup
Theresa Hui
theresahui@cuhk.edu.hk
+85235051698
Time Frame
Start Date: 2023-06-18
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 47
Treatments
AD
Patient aged greater than 18, presented to the ED with first 24 hours of symptoms suggesting AD, including chest pain, upper back pain, syncope of unknown cause, symptoms of any acute perfusion deficit and confirmed AD.
Healthy
Patients attending ED who do not have coronary disease, hypertension or aortic disease would be identified as healthy control.
Related Therapeutic Areas
Sponsors
Leads: Chinese University of Hong Kong

This content was sourced from clinicaltrials.gov